Managing IBD in Patients with Previous Cancers

Overview

Journal Frontline Gastroenterol

Specialty Gastroenterology

Date 2022 Jul 11

PMID 35812021

Authors

Sarah E Minnis-Lyons

Zara Aiken

Shien Chow

Shahida Din

Affiliations

Soon will be listed here.

Abstract

A frequent dilemma faced in the inflammatory bowel disease (IBD) clinic is how to best treat a patient with a previous cancer diagnosis. The changing demographics of our patient population will make this quandary more common. Previous guidance has emphasised the importance of lengthy postcancer drug holidays and cautious use of IBD therapies. However, accumulating evidence suggests this approach may be unnecessarily conservative. This review considers recent evidence on the safety of IBD drugs, cancer and recurrent cancer risk in patients with IBD and provides a framework for shared decision making involving patient, gastroenterologist and oncologist.

Citing Articles

Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine.

Mukhtar M, Mosli M Saudi J Gastroenterol. 2024; 30(3):126-137.

PMID: 38597333 PMC: 11198921. DOI: 10.4103/sjg.sjg_427_23.

Unmet Challenges in Patients with Crohn's Disease.

Scheurlen K, Parks M, MacLeod A, Galandiuk S J Clin Med. 2023; 12(17).

PMID: 37685662 PMC: 10488639. DOI: 10.3390/jcm12175595.

Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases.

Khoshnam-Rad N, Vahedi H, Sadeghi A, Rastegarpanah M, Namazi S, Anushiravani A Middle East J Dig Dis. 2023; 15(2):83-106.

PMID: 37546508 PMC: 10404092. DOI: 10.34172/mejdd.2023.327.

Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy.

Nardone O, Zammarchi I, Santacroce G, Ghosh S, Iacucci M Cancers (Basel). 2023; 15(8).

PMID: 37190315 PMC: 10136846. DOI: 10.3390/cancers15082389.

References

Beaugerie L, Brousse N, Bouvier A, Colombel J, Lemann M, Cosnes J . Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009; 374(9701):1617-25. DOI: 10.1016/S0140-6736(09)61302-7. View

Lichtenstein G, Rogler G, Ciorba M, Su C, Chan G, Pedersen R . Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2020; 27(6):816-825. PMC: 8128409. DOI: 10.1093/ibd/izaa199. View

Ytterberg S, Bhatt D, Mikuls T, Koch G, Fleischmann R, Rivas J . Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022; 386(4):316-326. DOI: 10.1056/NEJMoa2109927. View

Card T, Ungaro R, Bhayat F, Blake A, Hantsbarger G, Travis S . Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data. Aliment Pharmacol Ther. 2019; 51(1):149-157. PMC: 7050439. DOI: 10.1111/apt.15538. View

Lamb C, Kennedy N, Raine T, Hendy P, Smith P, Limdi J . British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019; 68(Suppl 3):s1-s106. PMC: 6872448. DOI: 10.1136/gutjnl-2019-318484. View

Sands B, Sandborn W, Panaccione R, OBrien C, Zhang H, Johanns J . Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019; 381(13):1201-1214. DOI: 10.1056/NEJMoa1900750. View

Sorensen H, Mellemkjaer L, Nielsen G, Baron J, Olsen J, Karagas M . Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst. 2004; 96(9):709-11. DOI: 10.1093/jnci/djh118. View

Turner D, Ricciuto A, Lewis A, DAmico F, Dhaliwal J, Griffiths A . STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2020; 160(5):1570-1583. DOI: 10.1053/j.gastro.2020.12.031. View

Porter R, Arends M, Churchhouse A, Din S . Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines. J Crohns Colitis. 2021; 15(12):2131-2141. PMC: 8684457. DOI: 10.1093/ecco-jcc/jjab102. View

10.

Cheddani H, Dauchet L, Fumery M, Charpentier C, Bouvier A, Dupas J . Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study. Am J Gastroenterol. 2016; 111(10):1428-1436. DOI: 10.1038/ajg.2016.304. View

11.

Bewtra M, Reed S, Reed Johnson F, Scott F, Gilroy E, Sandler R . Variation Among Patients With Crohn's Disease in Benefit vs Risk Preferences and Remission Time Equivalents. Clin Gastroenterol Hepatol. 2019; 18(2):406-414.e7. DOI: 10.1016/j.cgh.2019.05.010. View

12.

Axelrad J, Fowler S, Friedman S, Ananthakrishnan A, Yajnik V . Effects of cancer treatment on inflammatory bowel disease remission and reactivation. Clin Gastroenterol Hepatol. 2012; 10(9):1021-7.e1. DOI: 10.1016/j.cgh.2012.06.016. View

13.

Zheng K, Guo C, Wong I, Chen L, Chung H, Cheung K . Risk of malignancies in patients with inflammatory bowel disease who used thiopurines as compared with other indications: a territory-wide study. Therap Adv Gastroenterol. 2020; 13:1756284820967275. PMC: 7682226. DOI: 10.1177/1756284820967275. View

14.

Biancone L, Armuzzi A, Scribano M, DInca R, Castiglione F, Papi C . Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. J Crohns Colitis. 2016; 10(8):913-24. DOI: 10.1093/ecco-jcc/jjw048. View

15.

Sebastian S, Neilaj S . Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment?. Therap Adv Gastroenterol. 2019; 12:1756284818817293. PMC: 6322094. DOI: 10.1177/1756284818817293. View

16.

Honda S, Sakai R, Inoue E, Majima M, Konda N, Takada H . Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: Results from a Japanese multi-institutional retrospective study. Mod Rheumatol. 2021; 32(1):16-23. DOI: 10.1080/14397595.2020.1869370. View

17.

Feagan B, Sandborn W, Gasink C, Jacobstein D, Lang Y, Friedman J . Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016; 375(20):1946-1960. DOI: 10.1056/NEJMoa1602773. View

18.

Biancone L, Armuzzi A, Scribano M, Castiglione F, DInca R, Orlando A . Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study. Inflamm Bowel Dis. 2019; 26(3):450-459. DOI: 10.1093/ibd/izz155. View

19.

Selmaj K, Cohen J, Comi G, Bar-Or A, Arnold D, Steinman L . Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Mult Scler Relat Disord. 2021; 51:102844. DOI: 10.1016/j.msard.2021.102844. View

20.

Williams C, Peyrin-Biroulet L, Ford A . Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014; 39(5):447-58. DOI: 10.1111/apt.12624. View